The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

OBJECTIVES: Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low dose of pembrolizumab‐activated autologous dend...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Meng‐Jia, Pan, Qiu‐Zhong, Ding, Ya, Zeng, Jianxiong, Dong, Pei, Zhao, Jing‐Jing, Tang, Yan, Li, Jingjing, Zhang, Zhiling, He, Junyi, Yang, Jieying, Huang, Yue, Peng, Ruiqing, Wang, Qi‐Jing, Gu, Jia‐Mei, He, Jia, Li, Yong‐Qiang, Chen, Shi‐Ping, Huang, Rongxing, Zhou, Zi‐Qi, Yang, Chaopin, Han, Yulong, Chen, Hao, Liu, Heping, Xia, Shangzhou, Wan, Yang, Weng, De‐Sheng, Xia, Liming, Zhou, Fang‐Jian, Xia, Jian‐Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927618/
https://www.ncbi.nlm.nih.gov/pubmed/33717483
http://dx.doi.org/10.1002/cti2.1257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927618/
https://www.ncbi.nlm.nih.gov/pubmed/33717483
http://dx.doi.org/10.1002/cti2.1257

Ejemplares similares